肿瘤PET/CT：现状与争议

摘要(中文译文)

一体化PET/CT的引入显著提高了全球PET的增长速度，主要用于肿瘤成像，采用葡萄糖类似物18F-氟脱氧葡萄糖（FDG）。越来越多的文献表明，与单独PET、单独CT以及视觉关联的PET和CT相比，使用FDG-PET/CT以及由此获得的解读配准融合PET和CT图像的能力，可提高观察者的信心和诊断效能。随着正在开发的新型PET放射性药物，PET/CT的价值可能更大，其中许多药物产生的PET图像比FDG图像具有更少的解剖标志。PET/CT还可能使18F-氟化物重新成为放射性核素骨成像的主要药物。与PET/CT相关的争议有很多，包括对解读医师的最低培训和经验要求，以及定义技术和专业报销的新模式。

Abstract

The introduction of integrated PET/CT has dramatically increased the worldwide rate of growth for PET, predominantly for oncologic imaging with the glucose analog 18F-fluorodeoxyglucose (FDG). A rapidly expanding body of literature demonstrates that the use of FDG-PET/CT and the resultant ability to interpret coregistered and fused PET and CT images lead to improved observer confidence and improved diagnostic performance by comparison with PET alone, CT alone, and visually correlated PET and CT. The value of PET/CT is likely to be even greater with new PET radiopharmaceuticals under development, many of which produce PET images with even fewer anatomical landmarks than FDG images. PET/CT is also likely to lead to the resurrection of 18F-fluoride as a principal agent for radionuclide bone imaging. There are a number of controversies related to PET/CT, including minimum training and experience requirements for interpreting physicians and defining new models for technical and professional reimbursement.

如何引用